Loading...
•
Jun 30, 2021
Harrow Q2 2021 Earnings Report
Announced record results for the second quarter and first half ended June 30, 2021.
Key Takeaways
Harrow Health reported its best financial quarter in company history for Q2 2021, including new records in revenues, cash flow from operations, revenue per shipping day, and units shipped.
Second quarter of 2021 was the best financial quarter in company history.
Strengthened cash position by raising $75 million of unsecured capital.
Purchased rights to AMP-100, a patented, ophthalmic topical anesthetic drug candidate, in July 2021.
Expect a new drug application to be submitted to the FDA for AMP-100 in the next few months.
Forward Guidance
Harrow Health is positioning itself to deliver a more diverse range of products to its prescribers and attractive operational results to its stockholders in the second half of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...